ArticleVaccine2025
HPV vaccination among gay, bisexual, and other men who have sex with men aged 27-45 years in the United States is potentially Cost-saving.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Strategies implemented to increase HPV vaccine uptake and confidence among men who have sex with men and transgender people: A systematic review.Human vaccines & immunotherapeutics · 2026Pooled it
- Article
- HPV Vaccination Completion Among Men Who Have Sex with Men Using HIV Pre-Exposure Prophylaxis in Brazil: A Cross-Sectional Study.Vaccines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe Advisory Committee on Immunization Practices (ACIP) recommends routine human papillomavirus (HPV) vaccination at age 11 or 12 years (vaccination can be given starting at age 9 years), with catch-up vaccination for all persons through age 26 years. ACIP recommends shared clinical decision-making for HPV vaccination of persons aged 27 through 45 years, although modeling indicated that broadly vaccinating persons in this age group would not be cost-effective. To help inform clinical decision-making, the objective of this study was to estimate the cost-effectiveness of HPV vaccination among gay, bisexual, and other men who have sex with men (GBMSM) aged 27 through 45 years in the United States.
methodWe used an age-specific, compartmental, susceptible-infectious-susceptible (SIS) model of HPV transmission and disease among GBMSM to estimate changes in HPV, anogenital wart, and HPV-attributable cancer incidence when the upper age for vaccination among GBMSM was raised to age 30, 35, 40, or 45 years. We then estimated changes in quality adjusted life years (QALYs), costs (vaccination costs and direct medical costs of HPV disease), and the incremental cost-effectiveness ratio under each of these scenarios.
resultsOur estimates showed that HPV vaccination of GBMSM was cost-saving through age 45 years, i.e., the costs of vaccination are more than offset by decreases in the direct medical costs of HPV disease. Vaccination of GBMSM through at least age 40 years was cost-saving across most sensitivity analyses.
conclusionsVaccination of GBMSM through age 45 years is likely a cost-saving use of public health resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.